ArticleAnnals of translational medicine2017

The ODYSSEY DM-DYSLIPIDEMIA trial: confirming the benefits of alirocumab in diabetic mixed dyslipidemia.

Paul Chan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.